Chemistry: All solvents used in the reactions were p.A. grade. Solvents for chromatography were technical grade and distilled prior to use. Anhydrous dichloromethane and THF were obtained from an MBraun MB-SPS 800 solvent purification system. Commercial materials were purchased at the highest commercial quality from the providers abcr, Acros, Organics, Alfa Aesar, Carbolution, Carl Roth, Merck, Sigma Aldrich, VWR, Jena Biosciences and Thermo Fisher Scientific. These chemicals were used without further purification. Silica gel Geduran® Si 60 (particle size 0.40-0.60 mm) purchased from Merck, was used for flash column chromatography. Solvent mixtures are understood as volume/volume. For TLC analysis, TLC-silica gel 60 F254 plates were purchased from Merck. Applied substances were observed using a UV lamp at 254 nm. For UV-inactive substances, dyeing reagents, such as 0.36% ninhydrin solution in ethanol were used. NMR spectra were recorded on Bruker AVHD300, Bruker AVHD400, Bruker AVHD500 (only 1 H NMR spectra), Bruker AV500-cryo, or Bruker Avance600 spectrometers. The chemical shifts δ are listed as parts per million [ppm] and refer to δ(TMS) = 0. The spectra were calibrated using residual undeuterated solvent as an internal reference (δ(CDCl3 ) = 7.26 ppm, δ(methanol-d4) = 3.31 ppm for 1 H NMR; δ(CDCl3) = 77.0 ppm, δ(methanol-d4) = 49.0 ppm for 13 C NMR). The following abbreviations are used to explain the multiplicities: bs = broad signal, s = singlet, d = doublet, dd = doublet of doublets, ddd = doublet of doublets of doublets, t = triplet, dt = doublet of triplets, m = multiplet.
Chemo-Enzymatic Synthesis
2.1. Enzymatic Synthesis of Sorbicatechol A (7a) [2] Scheme S1. Synthesis of sorbicatechol A (7a).
Sorbicillin (1) (40.0 mg, 172.4 μmol, 1.0 eq.) was dissolved in acetone (8 mL) and added to phosphate buffer (40 mL, 50 mM, pH = 8) with the enzyme SorbC (1.75 mL, 13 .0 mg/mL in Tris buffer). The reaction was started by addition of NADH (150.0 mg, 227.8 μmol, 1.3 eq.) and incubated for 6 h at rt. The reaction mixture was extracted with dichloromethane (3 x 100 mL), 2methoxy-4-vinylphenol (9a) (72.3 mg, 482.0 μmol, 2.8 eq.) was added and the solvent was evaporated under reduced pressure, to increase the concentration of the dienophile slowly over time. Purification by preperative HPLC (retention time -analytical HPLC: 10.66 min). The desired product sorbicatechol A (7a) was obtained in 30 % isolated yield (20.6 mg, 51.7 μmol, 30%). 1 H NMR (600 MHz, CDCl3) δ = 14.33 (s, 1 H), 7.37 (dd, J = 14.9, 10.9 Hz, 1 H), 6.78 (d, J = 8.1 Hz, 1 H), 6.48 (dd ,J = 8.1, 2.0 Hz,1 H), 6.44 (d, J = 2.0 Hz, 1 H), 6.36-6.19 (m, 3 H), 3.78 (s, 3 H) , 3 .29 (t, J = 2.6 Hz, 1 H), 3.08-2.98 (m, 2 H), 1.92 (d, J = 6.6 Hz, 3 H), 1.84 (ddd, J = 12.8, 4.4, 2. 9 Hz 1 H), 1.26 (s, 3 H), 0.92 (s, 3 H) . 13 C NMR (125 MHz, CDCl3) δ = 212. 0, 198.0, 167.2, 146.6, 145.0, 142.6, 140.1, 133.3, 131.0, 121.6, 118.1, 114.4, 112.2, 110.4, 75.0, 65.2, 55.8, 47.8, 40.6, 31.5, 24.4, 19.1, 10.7. HRMS (ESI+) : m/z 399.1802 [M+H] + , calc.: 399.1802. [α]D = -62.4° (c = 3.5 in MeOH). The physical and spectroscopic data were in agreement with that described in the literature. [3] 2.2. Enzymatic Synthesis of Derivatives 7b-o Scheme S2. Synthesis of sorbicatechol derivatives. [2] Sorbicillin (1) (40.0 mg, 172.4 μmol, 1.0 eq.) was dissolved in acetone (8 mL), and added to phosphate buffer (50 mL, 50 mM, pH = 8) with the enzyme SorbC (3.0 mL, 8.2 mg/mL in Tris buffer). The reaction was started by addition of NADH (150.0 mg, 227.8 μmol, 1.3 eq.) and incubated for 4-6 h at rt. The reaction mixture was extracted with dichloromethane (3 x 100 mL), vinyl compound 9b-o (1.0 mL / in excess) was added and the solvent was evaporated under reduced pressure. Purification by preperative HPLC (retention time: Rt). The desired products 7b-o were obtained in 21-32% isolated yield. 7b: 1 H NMR (500 MHz, CDCl3) δ = 14.31 (bs, 1 H), 7.38 (dd, J = 15.0, 10.9 Hz, 1 H), 7.06 (d, J = 8.0 Hz, 2 H), 6.84 (d, J = 8.1 Hz, 2 H), 6.44-6.16 (m, 3 H), 3.29 (t, J = 2.9 Hz, 1 H), 3.09 (dd, J = 10.7, 5.7 Hz, 1 H), 3.00 (ddd, J = 13.6, 10.7, 3.0 Hz, 1 H), 2.29 (s, 3 H), 1.91 (d, J = 6.7 Hz, 3 H), 1.85 (ddd, J = 13.4, 5.7, 2.8 Hz ,1 H), 1.26 (s, 3 H), 0.90 (s, 3 H) . 13 C NMR (125 MHz, CDCl3) δ = 211.9, 197.9, 167.2, 142.5, 139.9, 138.4, 137.2, 131.0, 129.5, 129.5, 128.3, 128.3, 118.2, 112.2, 74.9, 64.9, 47.6, 40.6, 31.4, 24.5, 21.1, 19.1, 10.7 (dd, J = 14.9, 11.0 Hz, 1 H), 7.30 (d, J = 8.6 Hz, 2 H), 7.17 (d, J = 8.6 Hz, 2 H), 6.49 (d, J = 15.0 Hz, 1 H), 6.43 (dd, J = 15.0, 11.0 Hz, 1 H), 6.25 (dd, J = 14.8, 7.1 Hz, 1 H), 3.36-3.33 (m, 1 H), 3.29 (d, J = 6.2 Hz, 1 H), 3.05 (ddd, J = 13.7, 10.6, 3.1 Hz, 1 H), 1.90 (d, J = 6.8 Hz ,3 H), 1.82 (ddd, J = 13.5, 6.1, 2.7 Hz, 1 H), 1.23 (s, 3 H), 0.79 (s, 3 H) . 13 C NMR (125 MHz, MeOD) δ = 210.6, 199.1, 168.4, 161.7, 161.4, 144.7, 143.8, 140.6, 132.3, 131.3, 131.2, 124.2, 119.5, 113.6, 75.1, 65.8, 47.3, 42.2, 32.6, 23.9, 18.9, 11.3. HRMS (ESI+) 9, 197.9, 167.2, 158.9, 142.6, 139.9, 133.4, 131.0, 129.5, 129.5, 118.2, 114.1, 114.1, 112.1, 74.9, 65.1, 55.4, 47.3, 40.6, 31.5, 24.5, 19.1, 10.7 6, 198.0, 167.3, 142.6, 140.4, 139.9, 136.4, 131.0, 130.5, 127.1, 127.0, 127.0, 118.2, 112.2, 74.8, 65.1, 41.2, 40.5, 32.0, 24.5, 20.4, 19.1, 9.7 3, 195.9, 167.1, 157.0, 142.5 139.8, 130.9, 129.7, 129.7, 121.6, 117.9, 115.7, 115.7, 110.2, 77.3, 74.7, 66.4, 39.9, 31.0, 24.5, 19.1, 9. 1, 196.6, 166.6, 142.0, 139.4, 131.0, 118.1, 110.5, 79.3, 74.7, 67.1, 65.8, 39.9, 30.8, 24.5, 19.0, 15.2, 9.1 . The physical and spectroscopic data were in agreement with that described in the literature. [4] 7h: 1 H NMR (500 MHz, CDCl3) δ = 13.94 (bs, 1 H), 7.29 (dd, J = 14.2, 10.0 Hz, 1 H), 6.37-6.06 (m, 3 H), 3.54 (dd, J = 8.3, 2.5 Hz, 1 H), 3.48 (dt, J = 9.4, 6.4 Hz, 1 H), 3.32-3.23 (m, 1 H), 3.15 (t, J = 3.0 Hz, 1 H), 2.76 (ddd, J = 13.8, 8.3, 2.6 Hz, 1 H), 1.89 (d, J = 6.7 Hz, 3 H), 1.67 (dt, J = 13.7, 3.1 Hz, 1 H), 1.51-1.41 (m, 2 H), 1.32 (s, 3 H), 1.35-1.25 (m, 2 H), 1.20 (s, 3 H), 0.86 (t, J = 7.3 Hz, 3 H). 13 C NMR (125 MHz, CDCl3) δ = 211. 1, 196.6, 166.4, 141.9, 139.3, 131.0, 118.2, 110.5, 79.6, 74.8, 70.1, 67.3, 39.9, 31.8, 30.6, 24.5, 19.4, 19.0, 14.0, 9.1 . The physical and spectroscopic data were in agreement with that described in the literature. [5] 7i: 1 H NMR (500 MHz, CDCl3) δ = 14.00 (bs, 1 H), 7.31 (dd, J = 14.9, 10.7 Hz, 1 H), 6.30-6.14 (m, 3 H), 3.73 (dd, J = 8.5, 2.6 Hz, 1 H), 3.11 (t, J = 3.0 Hz, 1 H), 2.81 (ddd, J = 13.7, 8.5, 2.6 Hz, 1 H), 1.89 (d, J = 6.8 Hz, 3 H), 1.64 (dt, J = 13.7, 3.1 Hz, 1 H), 1.24 (s, 3 H), 1.19 (s, 3 H), 1.11 (s, 9 H) . 13 C NMR (125 MHz, CDCl3) δ = 211. 8, 197.0, 166.2, 141.8, 139.2, 131.0, 118.2, 110.7, 74.7, 72.2, 66.9, 40.0, 34.9, 28.6, 28.6, 28.6, 28.5, 24.4, 19.0, 9.6 5, 196.3, 166.9, 142.4, 139.8, 131.0, 117.9, 110.4, 80.0, 74.6, 71.4, 67.1, 61.9, 39.8, 30.5, 24.4, 19.1, 9.2 3, 197.0, 190.7, 165.5, 165.2, 148.0, 144.5, 130.3, 130.0, 130.0, 129.9, 129.2, 128.8, 128.8, 121.3, 74.5, 73.0, 67.6, 46.5, 27.2, 24.3, 19.3, 9.8 6, 210.0, 196.4, 167.0, 142.3, 139.6, 131.0, 118.0, 110.8, 74.9, 61.7, 50.7, 40.3, 37.6, 26.3, 24.3, 19.0, 10.4, 7.5 208.0, 195.9, 168.8, 158.5, 143.9, 143.7, 143.6, 141.2, 131.0, 124.8, 124.7, 117.7, 111.8, 74.5, 63.2, 44.4, 40.6, 30.8, 24.2, 19.2, 10.4 5, 196.0, 169.0, 152.8, 147.7, 143.9, 141.2, 135.6, 130.9, 117.6, 111.4, 74.8, 64.7, 40.3, 39.8, 33.4, 24.5, 19.2, 14.3, 10 7, 196.4, 167.0, 157.1, 145.4, 143.7, 142.4, 142.3, 139.7, 131.0, 118.2, 111.9, 74.9, 63.5, 45.7, 40.5, 29.4, 24.4, 19.1, 10.7 (EASY-HIT) . The EASY-HIT assay is based on HIV-1 susceptible reporter cells (LC5-RIC) that contain a stably integrated fluorescent reporter gene that is activated upon successful HIV-1 infection and expression of the early viral protein HIV-Rev and HIV-Tat. Briefly, LC5-RIC cells were seeded into black 96-well plates at a density of 10,000 cells per well 24 hours before infection and treatment of the cells. Compounds stocks dissolved at 100 mM in DMSO were screened at multiple concentrations from 3 to 10 μM at a final DMSO concentration of 0.1% to establish IC50 curves. After compound addition, LC5-RIC cells were infected by adding HIV-1LAI inoculum at an MOI of 0.5 to each well of the plate. Cells were incubated at 37 °C, 5% CO2 for 48 hours after infection and then measured for reporter expression. Reporter expression was determined by measuring the total fluorescent signal intensity of each well using a fluorescence microplate reader at an excitation filter wavelength of 552 nm and an emission filter wavelength of 596 nm.
Anti-Viral Screening

HIV-Tests
HIV Full virus Screening
Cell viability assays. Cell viability of LC5-RIC cultures exposed to HIV-1LAI inoculum and test compounds was determined by performing a CellTiter-Blue® cell viability assay (Promega) and monitoring the ability of metabolically active cells to convert the redox dye resazurin into the fluorescent product resorufin. LC5-RIC cells were seeded into black 96-well plates at a density of 10,000 cells per well followed by overnight incubation at 37 °C, 5% CO2. Compounds stocks dissolved at 100 mM in DMSO were screened at multiple concentrations from 3 to 100 μM at a final DMSO concentration of 0.1% followed by an additional 48 hours incubation. After the designated incubation time, CTB reagent (1:5 in cell culture medium) was added to each well. CTB containing plates were incubated for an additional hour after which fluorescence signal of resorufin was measured using a fluorescence microplate reader at an excitation filter wavelength of 550 nm and an emission filter wavelength of 600 nm.
Influenza-Tests
Influenza A inhibition and cell viability assay: A549 cells were seeded into 96-well-plates at a density of 20,000 cells per well 24 hours before infection and treatment on the cells. Compounds stocks (5, 5b, 5m, 5k ) dissolved at 500 mM in DMSO were screened at multiple concentrations from 5 mM serially diluted in DMEM to 0,25 μM (1:3) . After compound addition, A549 cells were infected with Influenza A virus (strain SC35M) encoding Gaussia luciferase (PMID: 26068081) at an MOI of 0.01. Cells were incubated at 37 °C, 5% CO2 and gaussia luciferase accumulation was evaluated after 24, 48 and 72 hours. For testing cell viability, a reazurine reduction assay was performed at 48h post drug treatment (Citea PMID: 29255269). Figure S1 . Activity of compounds on influenza A virus replication. Cells were treated with the indicated concentration of compound and infected with influenza A virus expressing gaussia luciferase. 24h, 48h and 72h later the supernatant was assayed for accumulation of gaussia luciferase (left). At 48h and 72h a resazurine conversion assay was used to test cell viability. Graph show representative experiments. Error bars: SD of duplicate measurements. Figure S1 . Activity of compounds on influenza A virus replication. Cells were treated with the indicated concentration of compound and infected with influenza A virus expressing gaussia luciferase. 24h, 48h and 72h later the supernatant was assayed for accumulation of gaussia luciferase (left). At 48h and 72h a resazurine conversion assay was used to test cell viability. Graph show representative experiments. Error bars: SD of duplicate measurements. Figure S2 . 1 Figure S4 . NOESY spectrum of sorbicatechol A (7a) in CDCl3. Blue arrows illustrate missing correlation between 1-CH3 and 17-OCH3 which would be necessary for exo-orientation. [3] 46 30.97 39.87 66.38 74.72 77.16 CDCl3 77.30 110.15 115.68 117.87 121.56 129.71 130.93 139.84 142.48 157.01 167.14 195.85 210.31 7f Figure S11 . 1 Figure S24 . 13 
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